UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23

UBS analyst Ashwani Verma has downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from a Buy rating to Neutral. Additionally, the price target for the stock has been reduced significantly from $49 to $23.